Technical Analysis for BMRN - BioMarin Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade D 67.9 -0.06% -0.04
BMRN closed down 0.06 percent on Thursday, October 17, 2019, on approximately normal volume.

Earnings due: Oct 24

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical BMRN trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
20 DMA Resistance Bearish -0.06%
Inside Day Range Contraction -0.06%
20 DMA Resistance Bearish -0.89%
MACD Bullish Signal Line Cross Bullish 0.98%
Gapped Up Strength 0.80%
Up 3 Days in a Row Strength 0.80%
Oversold Stochastic Weakness 2.10%

Older signals for BMRN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company's commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It also develops Vimizim, an enzyme replacement therapy that is in phase III clinical stage for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; BMN-673, a clinical Phase I/II trial product for the treatment of cancer; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of BH4 in Kuvan for PKU and for other indications, and PEG-PAL. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Medicine Health Cancer California Treatment Of Cancer Drug Discovery Rare Diseases Virotherapy Serious Diseases Autoimmune Disease Inborn Errors Of Metabolism Biopharmaceuticals Enzyme Replacement Therapy Pompe Disease Pharmaceutical Wholesalers Phenylketonuria Achondroplasia Biomarin Pharmaceutical Genetic Disease Iduronidase Intellectual Disability Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Novato Pku
Is BMRN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 105.45
52 Week Low 62.88
Average Volume 1,190,730
200-Day Moving Average 83.7397
50-Day Moving Average 71.9031
20-Day Moving Average 68.0033
10-Day Moving Average 66.6995
Average True Range 1.8934
ADX 23.3
+DI 23.0455
-DI 21.0694
Chandelier Exit (Long, 3 ATRs ) 71.4248
Chandelier Exit (Short, 3 ATRs ) 68.5602
Upper Bollinger Band 74.1254
Lower Bollinger Band 61.8812
Percent B (%b) 0.49
BandWidth 18.005303
MACD Line -1.5219
MACD Signal Line -1.9801
MACD Histogram 0.4582
Fundamentals Value
Market Cap 11.9 Billion
Num Shares 175 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -63.46
Price-to-Sales 12.04
Price-to-Book 5.17
PEG Ratio -4.46
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 71.04
Resistance 3 (R3) 71.35 70.63 70.51
Resistance 2 (R2) 70.63 69.83 70.47 70.34
Resistance 1 (R1) 69.26 69.34 68.90 68.95 70.16
Pivot Point 68.54 68.54 68.36 68.38 68.54
Support 1 (S1) 67.17 67.74 66.81 66.86 65.64
Support 2 (S2) 66.45 67.25 66.29 65.46
Support 3 (S3) 65.08 66.45 65.29
Support 4 (S4) 64.77